Core Insights - Boundless Bio has appointed Dr. Robert Doebele as Chief Medical Officer, bringing over 15 years of oncology drug development experience to the company [1][2][3] Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA) to address oncogene amplified cancers, which affect over 14% of cancer patients [4] - The company is advancing its lead candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [4] Leadership and Experience - Dr. Doebele co-founded Rain Oncology, where he directed the development of therapies targeting oncogenic drivers and led clinical development plans for several innovative drugs [2] - He has a notable background in precision oncology, having contributed to the approval of Vitrakvi® and Rozlytrek® through his research on NTRK gene fusions [2] Strategic Focus - The company aims to deliver novel treatment options for patients with oncogene amplified cancers, addressing a significant unmet medical need in the oncology space [3][4]
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer